Atai Life Sciences (ATAI) Competitors $1.19 0.00 (0.00%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATAI vs. NUVB, AVBP, IMTX, REPL, QURE, ETNB, PLRX, RLAY, AVXL, and IMNMShould you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Immatics (IMTX), Replimune Group (REPL), uniQure (QURE), 89bio (ETNB), Pliant Therapeutics (PLRX), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. Atai Life Sciences vs. Nuvation Bio ArriVent BioPharma Immatics Replimune Group uniQure 89bio Pliant Therapeutics Relay Therapeutics Anavex Life Sciences Immunome Nuvation Bio (NYSE:NUVB) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation. Which has more risk and volatility, NUVB or ATAI? Nuvation Bio has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Does the MarketBeat Community favor NUVB or ATAI? Atai Life Sciences received 288 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 78.18% of users gave Nuvation Bio an outperform vote while only 66.33% of users gave Atai Life Sciences an outperform vote. CompanyUnderperformOutperformNuvation BioOutperform Votes4378.18% Underperform Votes1221.82% Atai Life SciencesOutperform Votes33166.33% Underperform Votes16833.67% Do institutionals & insiders hold more shares of NUVB or ATAI? 61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 5.1% of Nuvation Bio shares are owned by insiders. Comparatively, 31.2% of Atai Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend NUVB or ATAI? Nuvation Bio currently has a consensus price target of $6.60, suggesting a potential upside of 146.27%. Atai Life Sciences has a consensus price target of $9.00, suggesting a potential upside of 656.30%. Given Atai Life Sciences' higher possible upside, analysts plainly believe Atai Life Sciences is more favorable than Nuvation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NUVB or ATAI more profitable? Nuvation Bio's return on equity of -21.89% beat Atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Nuvation BioN/A -21.89% -17.86% Atai Life Sciences N/A -65.75%-52.71% Which has higher earnings & valuation, NUVB or ATAI? Atai Life Sciences has lower revenue, but higher earnings than Nuvation Bio. Atai Life Sciences is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$2.16M417.21-$75.80M-$2.17-1.24Atai Life Sciences$331K603.28-$40.22M-$0.81-1.47 Does the media prefer NUVB or ATAI? In the previous week, Nuvation Bio had 3 more articles in the media than Atai Life Sciences. MarketBeat recorded 3 mentions for Nuvation Bio and 0 mentions for Atai Life Sciences. Nuvation Bio's average media sentiment score of 0.62 beat Atai Life Sciences' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the media. Company Overall Sentiment Nuvation Bio Positive Atai Life Sciences Neutral SummaryNuvation Bio beats Atai Life Sciences on 10 of the 16 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Atai Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATAI vs. The Competition Export to ExcelMetricAtai Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$199.68M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.88%4.21%P/E Ratio-1.4710.5090.8317.14Price / Sales603.28195.361,112.01116.85Price / CashN/A57.1642.0237.88Price / Book0.815.104.774.78Net Income-$40.22M$151.51M$119.70M$225.60M7 Day Performance-12.50%-2.11%-1.86%-1.23%1 Month Performance-21.45%-3.11%11.45%3.07%1 Year Performance-8.46%11.53%30.43%16.48% Atai Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATAIAtai Life Sciences1.8723 of 5 stars$1.19flat$9.00+656.3%-9.8%$199.68M$331,000.00-1.4783Positive NewsHigh Trading VolumeNUVBNuvation Bio2.5897 of 5 stars$2.71+3.8%$6.60+143.5%+90.1%$912.11MN/A0.0060News CoverageAVBPArriVent BioPharma0.9763 of 5 stars$26.88+0.6%$36.80+36.9%N/A$905.78MN/A0.0040News CoveragePositive NewsIMTXImmatics1.4231 of 5 stars$7.34+1.8%$16.67+127.1%-25.3%$876.07M$115.50M-10.92260REPLReplimune Group4.534 of 5 stars$12.74+1.5%$17.29+35.7%+67.4%$871.67MN/A-4.11210Insider TradeQUREuniQure3.496 of 5 stars$17.43+13.2%$32.13+84.3%+172.3%$849.59M$28.59M-3.36500Analyst ForecastETNB89bio1.7797 of 5 stars$7.89+2.6%$30.33+284.5%-22.4%$837.33MN/A-2.6440News CoveragePositive NewsPLRXPliant Therapeutics3.3603 of 5 stars$13.60+2.3%$40.50+197.8%-19.0%$827.56M$1.58M0.0090RLAYRelay Therapeutics2.2515 of 5 stars$4.89+3.8%$20.50+319.2%-60.4%$818.49M$25.55M-1.80304Insider TradeAVXLAnavex Life Sciences3.4566 of 5 stars$9.27+9.6%$43.00+363.9%-2.5%$786.10MN/A-18.3640IMNMImmunome2.5408 of 5 stars$12.51-0.6%$28.83+130.5%+33.0%$780.84M$10.13M-1.5540Positive News Related Companies and Tools Related Companies NUVB Competitors AVBP Competitors IMTX Competitors REPL Competitors QURE Competitors ETNB Competitors PLRX Competitors RLAY Competitors AVXL Competitors IMNM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATAI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
